Head-to-head · WeighScore
Aquivia Health vs GoodRx
The verdict
Aquivia Health takes it — 72.2/100 to 69.6/100.
Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aquivia Health | GoodRx |
|---|---|---|
| WeighScore | 72.2/100 | 69.6/100 |
| Grade | C | C |
| Scorecard rank | #80 | #122 |
| Semaglutide | $149/mo | Not disclosed |
| Tirzepatide | $179/mo | $299/mo (brand Zepbound) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #80 · C
Strengths
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
- Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
- Self-pay model with no insurance required and no separate consultation fee
Where it loses points
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
- No LegitScript, PCAB, or BBB trust badges visible
- Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #122 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.